SPONSOR
Genfleet Therapeutics (Shanghai) Inc.
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2
Clinical Trials by Genfleet Therapeutics (Shanghai) Inc.
NCT06375733 Phase 1, Phase 2
Recruiting
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Large B-cell Lymphoma
NCT07259590 Phase 1, Phase 2
Recruiting
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
Advanced Solid Tumors Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology